United Therapeutics jumps after trial win against Liquidia

United Therapeutics

30/09/2026 18:00

** Shares of drugmaker United Therapeutics UTHR.O rise 13% to $543.99
** A Delaware federal court denies Liquidia's LQDA.O "Motion To Strike" in its patent infringement case against United Therapeutics
** The patent infringement trial centers on whether Liquidia's drug, Yutrepia, violates patents protecting United Therapeutics' dry-powder inhalation lung disease treatment, Tyvaso
** "This ruling is a meaningful positive for UTHR," says RBC Capital analyst Lisa Walter, adding the ruling "significantly clouds the path" for Yutrepia to compete
** The judge says United Therapeutics adequately discloses its "common ownership" argument and gives Liquidia enough notice of that defense
** "This is a key element of the case for Liquidia, and denial of the Motion To Strike has negative readthrough to the final decision on the case," says Raymond James analysts
** Liquidia shares were halted in afternoon trading
** As of last close, UTHR up 10.7% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))